BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
December 23 2024 - 6:00AM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company that intends to change its name to BeOne Medicines
Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on
January 2, 2025, reflecting its long-standing commitment to
delivering innovative oncology medicines globally.
“As we enter our 15th year, changing our ticker to ONC reflects
our unwavering commitment to leadership in oncology and mission to
deliver transformative medicines to cancer patients worldwide,”
said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “This
milestone inspires pride in all we have accomplished and fuels our
excitement for the future as we advance our innovative hematology
franchise and solid tumor pipeline, driving meaningful impact for
patients everywhere.”
The Company’s CUSIP number will remain unchanged. In addition,
the Company stock codes and stock names for The Stock Exchange of
Hong Kong and the STAR Market of the Shanghai Stock Exchange will
not change. No action by the Company’s shareholders is required to
implement the Nasdaq ticker symbol change.
The Company will participate in the 43rd Annual J.P. Morgan
Healthcare Conference on Monday, January 13, 2025, with a
presentation at 1:30 pm PT. The live webcast of the event can be
accessed from the Investors section of the Company’s website at
http://ir.beigene.com/, https://hkexir.beigene.com/,
https://sseir.beigene.com/. An archived replay will be available
for 30 days following the event.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a
global oncology company that is discovering and developing
innovative treatments that are more affordable and accessible to
cancer patients worldwide. With a broad portfolio, we are
expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of nearly
11,000 colleagues spans five continents. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn, X
(formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s leadership in oncology; BeiGene’s ability to advance its
hematology franchise and solid tumor pipeline and the related
impact on patients; and BeiGene’s plans, commitments, aspirations
and goals under the caption “About BeiGene.” Actual results may
differ materially from those indicated in the forward-looking
statements as a result of various important factors, including
BeiGene’s ability to demonstrate the efficacy and safety of its
drug candidates; the clinical results for its drug candidates,
which may not support further development or marketing approval;
actions of regulatory agencies, which may affect the initiation,
timing and progress of clinical trials and marketing approval;
BeiGene’s ability to achieve commercial success for its marketed
medicines and drug candidates, if approved; BeiGene's ability to
obtain and maintain protection of intellectual property for its
medicines and technology; BeiGene’s reliance on third parties to
conduct drug development, manufacturing, commercialization, and
other services; BeiGene’s limited experience in obtaining
regulatory approvals and commercializing pharmaceutical products;
BeiGene’s ability to obtain additional funding for operations and
to complete the development of its drug candidates and achieve and
maintain profitability; and those risks more fully discussed in the
section entitled “Risk Factors” in BeiGene’s most recent quarterly
report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene’s subsequent
filings with the U.S. Securities and Exchange Commission. All
information in this press release is as of the date of this press
release, and BeiGene undertakes no duty to update such information
unless required by law.
To access BeiGene media resources, please visit our News
& Media site.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241223168194/en/
Investor Contact Liza Heapes +1 857-302-5663
ir@beigene.com
Media Contact Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Nov 2024 to Dec 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Dec 2023 to Dec 2024